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Abstract 
 
Background - It is a familiar story. A promising Multiple Sclerosis (MS) treatment 
clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the 
fourth: cost-effectiveness. This has led to concerns about the validity of the 
measures typically used to quantify treatment effects in cost-effectiveness analyses 
and in 2012, in the United Kingdom, the National Institute for Health and Care 
Excellence called for an improvement in the cost-effectiveness framework for 
assessing MS treatments. 
Objective and Methods - This review describes what is meant by cost-effectiveness 
in health/social care funding decision-making, and usual practice for assessing 
treatment benefits.  
Results - We detail the use of the quality-adjusted life-year (QALY) in resource 
allocation decisions, and set out limitations of this approach in the context of MS.  
Conclusion - We conclude by highlighting methodological and policy developments 
which should aid addressing these limitations.  
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Introduction 
 
It is a familiar story. A promising treatment for people with Multiple Sclerosis (MS) 
clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the 
fourth: cost-effectiveness. For the past two decades, from disease-modifying drugs, 
such as the interferons, to symptomatic treatments, like fampridine and sativex, the 
pattern has been the same. Clinicians and patients feel the treatment provides 
benefits, but the National Institute for Health and Care Excellence (NICE) states the 
benefits are not worth the costs, and it will not be funded by the National Health 
Service (NHS). This has led to concerns about the relevance and validity of the 
measures typically used to quantify treatment effects in cost-effectiveness analyses1 
and, in 2012 NICE called for an improvement in the cost-effectiveness framework for 
assessing treatments for people with MS2. 
 
This review describes what is meant by cost-effectiveness in health/social care 
funding decision-making, and usual practice for assessing treatment benefits. We 
set-out limitations of this approach, with illustrations in the MS context, and conclude 
by highlighting methodological and policy developments to address such limitations.  
 
 
Cost-effectiveness  
 
The public funding of health/social care interventions largely depends on 
demonstrating cost-effectiveness. This is assessed by weighing the additional costs 
of treatments against the additional benefits they provide3. In the UK4 and other 
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national health policy contexts e.g. Germany, the Netherlands, Australia and 
Canada, cost-effectiveness analyses include estimating the cost-per-QALY (quality-
adjusted life-year) of interventions. 
 
 
Quality-adjusted life-years (QALYs) 
 
The QALY combines length and quality-of-life in a single outcome measure. Each 
year of life is weighted by quality-of-life during that time. Quality-of-life is represented 
by QALY weights on a scale from zero (equivalent to being dead) to one (perfect 
health). QALY weights can also be negative, representing quality-of-life thought 
worse than being dead. A higher number of QALYs indicates a better health 
outcome.  
 
An advantage of the QALY is its applicability to a variety of conditions and 
interventions, providing a common metric to compare cost-effectiveness. This largely 
explains its appeal for informing system-wide funding decisions4,5,6,7.  
 
 
QALY weights and preference-based measures (PBMs) 
 
The quality-of-life ratings used as QALY weights are most commonly obtained from 
an existing preference-based measure (PBM) of health-related quality-of-life 
(HRQoL), such as the EQ-5D8 or the SF-6D9. PBMs have two components:  
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1) A descriptive system – This describes an individual’s health on a number of 
dimensions (e.g. mobility, pain), each with a number of severity levels. Each 
combination of levels/dimensions constitutes a ‘health state’. These descriptive 
systems (e.g. the EQ-5D) are often completed by individuals in clinical trials. 
 
2) QALY weights for health states - Tariffs of QALY weights pre-exist for commonly 
used PBMs e.g. a tariff of QALY weights was obtained for the health states that the 
EQ-5D describes via a representative sample of the UK general population. The tariff 
is used to apply QALY weights to EQ-5D health states reported by individuals in 
clinical trials and defined in cost-effectiveness models8.  
 
QALY weights are usually derived by eliciting people’s preferences for a sub-group 
of the descriptive system’s health states (and statistically modelling preferences for 
the remaining states). Preferences are obtained using a variety of methods which 
provide weights on the zero to one scale.  
 
 
QALY weights and MS 
 
QALY weights can have a major impact on cost-effectiveness results10, but there are 
inconsistencies and marked variability in reported weights11. For example, the UK 
MS Survey12 reported higher (i.e. better) EQ-5D scores at Expanded Disability 
Status Scale (EDSS) score 4 (‘Relatively severe disability’) compared to EDSS 3 
(‘Moderate disability’). These weights have been used in NICE appraisals of 
ocrelizumab, dimethyl fumarate, fingolimod and natalizumab. In addition, the QALY 
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weight decrement of 0.071 associated with a relapse12 has been widely used, but 
decrements of between 0.02913 and 0.814 have also been cited.  
 
 
Characteristics of QALY weights 
 
Three key areas of debate surround the current QALY approach: how to describe 
health states, whose preferences to use, and the scope of the health state 
description. These concerns are relevant to the validity of the QALY approach to MS. 
 
1. Generic PBMs 
The QALY weights most frequently used are from generic PBMs, designed to be 
maximally suitable for various conditions/interventions. Internationally, the EQ-5D is 
the most frequently used8 and is specified for use in NICE’s ‘reference case’4.  
 
2. General population preferences 
Typically QALY weights are elicited from members of the general population, the 
approach recommended in many policy settings, e.g. NICE4 and the Panel on Cost-
Effectiveness in Health and Medicine3. This is based on the argument that in 
publicly-funded healthcare systems societal preferences should guide resource 
allocation to reflect the views of those funding the service.  
 
3. HRQoL 
QALY weights are based on people’s health state preferences e.g. the EQ-5D 
includes the dimensions mobility, usual activities, pain/discomfort, self-care and 
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anxiety/depression. When QALY weights are applied to these health states the 
instruments are described as measuring health-related quality-of-life. 
 
 
 
Potential limitations of the QALY for MS 
 
 
1. Generic PBMs 
 
Relevance and responsiveness are key properties of any measure. Relevance 
concerns an instrument’s coverage of domains central to the measurement construct 
and important to the population, and is typically assessed by exploring content, 
convergent and discriminative validity. Convergent validity is the relationship with 
other measures that assess the same construct. Discriminative validity is the ability 
to distinguish between groups known to differ in the construct of interest15. 
Responsiveness is an instrument’s ability to detect changes in the construct it 
measures. A measure with poor responsiveness may fail to capture benefits (or 
harms) of a treatment.  
 
The relevance of the content of generic PBMs to MS has been questioned16,12. A 
recent systematic review16 concluded that the content validity of the EQ-5D and the 
SF-6D is poor, largely due to omission of domains relating to fatigue (EQ-5D), 
mobility (SF-6D), and cognition (both measures). A lack of convergent validity of 
generic PBMs with other HRQoL measures in relation to MS has also been 
8 
 
described16. Some research suggests that the EQ-5D and SF-6D distinguish 
between degrees of MS disability, whilst other work indicates a limited ability to 
capture changes in HRQoL across disease severity. Concerns have also been 
raised regarding the responsiveness of these generic PBMs to illness-related events 
and treatment effects. To date, no MS papers have been identified which explore the 
responsiveness of PBMs16 . 
 
 
2. General population preferences 
 
Basing QALY weights on general population preferences does not take specific 
account of the preferences of people with MS. Two main arguments support the use 
of patient preferences in cost-effectiveness analyses17. The first relates to welfare 
economics, which posits that the wellbeing of society equals the sum of the 
wellbeing of its individual members. This implies that decisions regarding public 
funding should be based on the preferences of those set to gain/lose directly from 
decisions made, rather than the wider population who may be unaffected. The 
second is that people with MS live with the condition and are better placed to assess 
how it affects quality-of-life. 
 
Qualitative research suggests differences in the rationales of people with MS and the 
general public for their health state preferences18, and significant differences have 
been identified between QALY weights from people with MS and the general 
population19. 
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3. HRQoL 
 
The particular conceptualisation of health-related quality-of-life used in relation to 
PBMs differs from its broader conceptualisation. HRQoL has been defined as, ‘the 
patient’s subjective perception of the impact of his [sic] disease and its treatment(s) 
on his [sic] daily life, physical, psychological and social functioning and well-being’20. 
In the framework of PBMs, HRQoL is operationalised as the preference weight 
assigned to an individual’s health state based (usually) on general population 
preferences for that health state. A change in a PBM score indicates a change in 
health status, represented by the associated change in preference weight.  
 
Treatments for people with MS can have effects beyond health and HRQoL as 
captured by PBMs. Interventions may have broader individual and/or societal 
impacts, e.g. engagement with community activities, employment. Despite the 
significance of these wider impacts, they have been under-represented in cost-
effectiveness analyses of MS treatments11. The discipline of health economics is 
founded on a societal perspective3, but the policy focus on the QALY has steered 
emphasis away from the effects of interventions on broader aspects of quality-of life-
and wellbeing. As such, treatment effects may be missed and cost-effectiveness 
analyses may not reflect the true impact of MS treatments on people’s lives1,11. 
 
 
 
Beyond the QALY and cost-effectiveness analyses of treatments for MS 
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Here we describe how each of these aforementioned QALY issues may be 
addressed in the context of MS.  
 
 
1. Development of MS-specific PBMs and QALY weights 
 
There is a tension in the use of generic PBMs. They must be sufficiently generic to 
apply to multiple conditions and interventions, and relevant to particular illnesses. 
The challenge of finding this balance has led to the development of condition-specific 
PBMs. 
 
Condition-specific PBMs comprise a descriptive system tailored to a particular 
illness, thus offering greater potential responsiveness. Three MS-specific PBMs have 
been developed21,22,23. The Preference-Based Multiple Sclerosis Index (PBMSI)21 is 
based on preferences elicited using a rating scale to produce a scoring algorithm. 
The Multiple Sclerosis Impact Scale-Preference Based Measure (MSIS-PBM)22 and 
the Multiple Sclerosis Impact Scale-Eight Dimensions (MSIS-8D)23 are based on 
responses to the Multiple Sclerosis Impact Scale-29 (MSIS-29). This measures the 
effect of MS on HRQoL and is commonly used in clinical trials. These latter 
measures enable QALY weights to be estimated from patient-level MSIS-29 data 
and facilitate retrospective analyses using existing data24.  
 
The use of condition-specific PBMs to provide QALY weights has generated 
considerable debate25. Some argue that to compare the results of cost-effectiveness 
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analyses the same descriptive system must be used to assess outcomes; others30 
suggest results are comparable providing the same preference elicitation methods 
are used. As such, health state preferences for the MSIS-PBM22 and the MSIS-8D23 
were elicited using NICE recommended methods4.  
 
Using a condition-specific rather than a generic PBM involves a trade-off between 
the advantages/disadvantages of the measures in relation to the condition of 
interest26. For MS, the potential limitations of generic PBMs support the use of a 
condition-specific PBM, and there is some evidence that these are more sensitive to 
differences across the range of HRQoL than generic PBMs23.  
 
 
2. QALY weights from people with MS 
 
Neither the use of ‘patient’ or ‘public’ preferences to inform resource allocation 
decisions can claim superior theoretical or empirical validity. However, within health 
policy contexts that are increasingly patient-centred27, it seems pertinent to consider 
the role of patient preferences in cost-effectiveness analyses.  
 
The PBMSI21 is based on preferences of people with MS, and the MSIS-8D has 
tariffs of public28 and patient29 QALY weights. Comparison of the MSIS-8D public 
and patient tariffs has highlighted differences. People with MS placed greater value 
on the health states than did the general population, a difference which was 
significant regardless of the severity of the health states. The general population 
placed greater importance on depression, fatigue and daily activities, and people 
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with MS placed greater importance on cognition. These findings suggest the impact 
of using patient rather than public QALY weights on the results of cost-effectiveness 
analyses will vary, depending on the specific dimensions of HRQoL affected by the 
intervention assessed e.g. interventions targeting cognition may appear more cost-
effective if assessed using QALY weights from people with MS19. The choice of 
‘whose preferences’ to use when estimating QALYs could have important 
consequences for reimbursement decisions19. 
 
Cost-effectiveness based on patient preferences could be considered in conjunction 
with results based on population preferences, yet NICE currently stipulates that 
QALY weights should be based on general population preferences4. Given the 
central role of cost-effectiveness analyses in resource allocation decisions, it seems 
judicious to find additional ways of building what is relevant and important to people 
with MS into research. The need for meaningful public and patient involvement (PPI) 
is indicated. Patients are experts at providing insight into the lived experience of a 
condition, as clinicians are experts at providing an overview of a disease, and health 
economists are experts in the methodology of cost-effectiveness analyses. 
 
Input from people with MS when developing the MSIS-8D34 resulted in the removal 
of several implausible health states from the preference elicitation survey. This is 
likely to have improved the validity of the QALY weights and enabled the MSIS-8D to 
provide a better indication of treatment impacts. Discussion of PPI in health 
economics research is growing, and our experiences of working with people with MS 
suggest involvement can be meaningful and productive in informing QALY 
developments. 
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3. Beyond HRQoL   
 
In 2013, NICE’s remit was extended from making funding recommendations about 
healthcare interventions to producing social care guidance30. This has led to 
increased scrutiny of the dominance of the health-related QALY31, and a greater 
focus in health/social care policy on measuring broader benefits. NICE30 and the 
Social Care Institute for Excellence (SCIE)32 have recommended that evaluations of 
interventions with a social care element should  include their impact on ‘wellbeing’.  
 
Wellbeing refers to being able to do and be the things in life that matter to 
individuals33. This seems particularly relevant to MS, given its wide-ranging impact 
and the breadth of interventions which may help e.g. rehabilitation programmes to 
support return-to-work, home adaptations and personal care. NICE now 
recommends the ICEpop CAPability measure for Adults (ICECAP-A)34 and the Adult 
Social Care Outcomes Toolkit (ASCOT)35; measures that extend beyond health to 
capture this wider construct. The ICECAP-A focuses on attachment, security, role, 
enjoyment and control. The ASCOT measures social care-related quality-of-life and 
includes: control over daily life; personal cleanliness and comfort; food and drink; 
personal safety; social participation and involvement; occupation; accommodation 
and; dignity. Both measures have a tariff of ‘wellbeing weights’ (akin to QALY 
weights), which indicate people’s preferences for the wellbeing states they describe. 
They are yet to be used in cost-effectiveness analyses of MS treatments, and their 
relevance and responsiveness need to be assessed in relation to MS. 
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Conclusion 
 
The way that treatment benefits are currently captured for health policy decision-
making has limitations in relation to MS. Generic PBMs may be limited in their 
relevance to MS and to fluctuations in the illness; the use of general public health 
state preferences may miss the lived experience of MS; and the operationalisation of 
HRQoL based on PBMs may not detect broader treatment impacts.  
 
Going beyond the established QALY approach is timely given recent and unfolding 
methodological and policy developments. MS-specific QALY measures are available 
for use alongside generic PBMs, with patient, as well as general public, tariffs. PPI in 
MS cost-effectiveness outcome assessment is developing, and NICE’s acceptance 
of wellbeing measures provides an opportunity to capture wider treatment impacts.  
 
The collaboration of health economists, clinicians, people with MS, and those 
supporting people with MS, to develop the methods used for measuring the benefits 
of treatments in cost-effectiveness analyses, and influence the resource allocation 
policy framework seems key. Since the 1990s huge progress has been made in 
relation to the third regulatory hurdle of efficacy, with the advent of, and engagement 
with, evidence-based medicine. A joint enterprise addressing the fourth hurdle of 
cost-effectiveness should help facilitate its successful negotiation. 
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